Quick Facts / Company Snapshot
| Metric | Value |
| Ticker | NASDAQ: TECH |
| Headquarters | Minneapolis, Minnesota |
| Founded | 1976 |
| IPO Year | 1985 |
| CEO | Kim Kelderman |
| CFO | James Hippel |
| Total Employees | Approximately 3,100 |
| Total Revenue (FY2025) | $1,219,635,000 |
| Gross Margin (GAAP) | 64.8% |
| Adjusted Gross Margin | 70.4% |
| Operating Income | $102,255,000 |
| Net Earnings | $73,400,000 |
| Diluted EPS (Adjusted) | $1.92 |
| Total Assets | $2,557,868,000 |
| Total Liabilities | $639,060,000 |
| Total Shareholders’ Equity | $1,918,808,000 |
| Operating Cash Flow | $287,556,000 |
| Capital Expenditures | $31,006,000 |
| R&D Expense | $99,496,000 |
| Dividends Paid | $50,391,000 |
Company Overview
Bio-Techne Corporation operates as a pivotal global developer and manufacturer of highly specialized life science tools, precision diagnostics, and bioactive reagents. The enterprise supplies the fundamental biological building blocks and analytical instruments required by researchers, pharmaceutical conglomerates, and clinical laboratories to decode complex diseases and manufacture advanced therapeutics.
By maintaining strict internal quality controls, the company produces hundreds of thousands of distinct products across a massive global manufacturing footprint. Bio-Techne categorizes its operational focus into three distinct vectors: the discovery of novel biological insights, the development of advanced therapeutics, and the enablement of precision diagnostics.
- 5% organic revenue growth was achieved in fiscal 2025, reaching a consolidated top line of over $1.2 billion and outpacing the broader life science tools sector.
- 31.6% adjusted operating margin was recorded for the full fiscal year, showcasing high sector profitability despite macro headwinds.
- Over 500 new products were introduced to the commercial market over the past fiscal year, demonstrating a rapid innovation cycle.
- Approximately 3,100 employees manage the company’s global operations, with 2,300 stationed in the United States and 800 located internationally.
The enterprise has systematically pursued a growth strategy that balances deep internal research and development with aggressive, targeted acquisitions. This dual approach allows the company to integrate cutting-edge spatial biology and cell therapy technologies into its core reagent business, establishing an end-to-end ecosystem for biopharmaceutical clients.
Business Segments
Bio-Techne divides its expansive operations into two primary reporting segments: the Protein Sciences Segment and the Diagnostics and Spatial Biology Segment.
Protein Sciences Segment
The Protein Sciences segment functions as the primary economic engine of the enterprise, delivering high-quality biological reagents and sophisticated proteomic analytical tools. The segment is subdivided into the Reagent Solutions division—producing cytokines, growth factors, antibodies, and small molecules—and the Analytical Solutions division, which manufactures automated protein analysis instruments.
- $870,245,000 in net sales were generated by this segment, representing 71.35% of total consolidated revenue for fiscal 2025.
- 5% organic revenue growth was achieved year-over-year within this division.
- 42.6% adjusted operating margin highlights the massive profitability and pricing power of the core reagent portfolio.
- Over 550 customers currently rely on the segment’s GMP-grade reagents for cell and gene therapy manufacturing.
This segment heavily targets biopharmaceutical companies, academic researchers, and contract research organizations. Recent product rollouts, including the next-generation “Leo” Simple Western instrument and the ProPak GMP Cytokine line, have deeply entrenched the segment into late-stage clinical manufacturing workflows.
Diagnostics and Spatial Biology Segment
The Diagnostics and Spatial Biology segment operates at the vanguard of clinical testing and tissue-based genomic analysis. It houses three distinct divisions: Spatial Biology (in-situ hybridization assays), Molecular Diagnostics (exosome-based liquid biopsies and genetic kits), and Diagnostic Reagents (FDA-cleared calibrators and controls).
- $346,263,000 in net sales were generated, accounting for 28.39% of total consolidated revenue.
- 6% organic growth was reported for the fiscal year, driven by robust molecular diagnostics performance and spatial biology adoption.
- Nearly 50% revenue growth was generated specifically by the Lunaphore COMET spatial biology platform.
- 6.2% adjusted operating margin was recorded, depressed temporarily by strategic growth investments and integration costs.
The spatial biology portfolio, branded largely under Advanced Cell Diagnostics (ACD), allows researchers to visualize RNA and protein targets at single-cell resolution. Meanwhile, the molecular diagnostics arm recently expanded its clinical utility through the launch of the AmplideX Nanopore Carrier Plus Kit and the ExoMut ESR1 Kit.
Other Revenue
A minor fraction of the company’s revenue is classified outside the main reporting segments due to strategic divestiture processes.
- $4,152,000 in net sales were attributed to “Other revenue,” representing just 0.26% of the consolidated total.
- December 31, 2023 marks the date a specific business unit met the held-for-sale criteria, necessitating this separate classification.
History and Evolution
The enterprise was originally founded in 1976 under the name Research and Diagnostic Systems, Inc., operating as a specialized provider of biological materials. It transitioned to the public markets in 1985 via a merger with Techne Corporation, which ultimately became the modern Bio-Techne Corporation.
- 1976: Official founding of the original operational entity.
- 1985: Achieved publicly traded status on the NASDAQ exchange.
- July 2022: Executed the acquisition of Namocell, Inc. for $101.2 million to integrate single-cell sorting technologies.
- March 2023: Invested $232 million for a 19.9% ownership stake in Wilson Wolf Manufacturing, securing access to scalable bioreactor technologies.
The modern era of the company has been defined by an aggressive acquisition strategy designed to assemble a comprehensive suite of life science tools. In July 2023, the company acquired Lunaphore Technologies SA for $169.7 million, fundamentally shifting its trajectory toward automated spatial biology. In August 2025, management announced the strategic divestiture of the Exosome Diagnostics business for $15 million to sharpen focus on core competencies.
Products and Services
The company’s revenue streams are intricately divided across consumables, capital equipment, and ongoing services, creating a sticky, recurring economic model.
Consumables
Consumables represent the core recurring revenue stream, encompassing single-use proteins, antibodies, immunoassays, and diagnostic quality controls. These products are integrated deeply into daily laboratory workflows.
- $972,286,000 in revenue was generated by consumables, making up 79.72% of total sales.
- $684,165,000 of consumable sales originated from the Protein Sciences segment.
- $283,969,000 of consumable sales were driven by the Diagnostics and Spatial Biology segment.
- Over 70,000 spatial biology probes are currently available in the catalog across 400 different species.
Instruments
Instruments serve as the capital equipment foundation that drives subsequent consumable utilization. This category includes automated western blotting machines, spatial biology processors, and single-cell sorters.
- $112,086,000 in revenue was derived from instrument sales, accounting for 9.19% of total revenue.
- 3 consecutive quarters of year-over-year growth were recorded in instrument revenue to close out the fiscal year.
Services
Services provide post-sale economic value through extended warranty contracts, post-contract technical support, custom development projects, and specialized laboratory testing.
- $111,570,000 in revenue was generated by services, representing 9.15% of total net sales.
- CLIA-certified laboratory services form a crucial part of this revenue, specifically regarding the processing of the ExoDx Prostate test.
Royalty Revenues
The enterprise monetizes its massive intellectual property portfolio by licensing proprietary technologies to external partners.
- $23,693,000 in revenue was captured through royalties, making up 1.94% of the consolidated total.
Brand Portfolio
Bio-Techne operates a constellation of highly respected legacy brands, unified under the global corporate identity to leverage cross-selling opportunities. (Specific brand revenue splits are not disaggregated from the overarching segment financials).
R&D Systems
Recognized as the foundational brand of the Protein Sciences segment, R&D Systems produces premium cytokines, growth factors, and antibodies. The brand also encompasses the analytical instruments division, providing automated protein analysis solutions.
Tocris Bioscience
Tocris specializes in the synthesis of high-purity small molecules, peptides, and chemical compounds utilized extensively in neurochemistry and pharmacological research.
Novus Biologicals
Novus acts as a massive repository for biological reagents, focusing primarily on a vast catalog of highly validated primary and secondary antibodies used in complex cellular investigations.
Advanced Cell Diagnostics (ACD)
ACD is the vanguard brand for the Spatial Biology division, housing the proprietary RNAscope, miRNAscope, and BaseScope in-situ hybridization assays.
- Over 12,000 peer-reviewed citations specifically reference ACD’s spatial biology technologies to date.
Lunaphore
Acquired in 2024, Lunaphore provides the COMET platform, a fully automated, high-throughput spatial biology solution capable of detecting up to 24 proteins and 12 RNA targets on a single slide.
Asuragen
Asuragen operates within the Molecular Diagnostics division, producing genetic carrier screening kits and oncology diagnostics, including the advanced AmplideX Nanopore Carrier Plus Kit.
ProteinSimple
ProteinSimple represents the analytical hardware legacy, driving the adoption of instruments like “Maurice” and “Leo” which streamline and automate traditional western blotting techniques.
Exosome Diagnostics
This brand focuses on liquid biopsy techniques, notably the ExoDx Prostate test. In August 2025, Bio-Techne entered an agreement to divest this brand to Mdxhealth for $15 million, though it will retain access to the core exosome technology for future kits.
Namocell
Acquired in 2022, Namocell produces single-cell sorting and dispensing platforms designed to preserve cell viability during complex biological workflows.
Geographical Presence
The enterprise maintains a sophisticated global footprint, optimizing supply chains and localized customer service across North America, Europe, and the Asia-Pacific region.
United States
The domestic market represents the operational nexus, housing the global headquarters and the majority of advanced manufacturing sites.
- $683,230,000 in revenue was captured in the US, accounting for 56.02% of the global total.
- Approximately 2,300 employees operate within the United States workforce.
EMEA, excluding United Kingdom
Europe serves as a critical growth vector for spatial biology and diagnostic adoptions. The company plans to open a massive Customer Service Center in Düsseldorf, Germany in 2026 to support the entire EMEA block.
- $266,305,000 in revenue was generated here, representing 21.83% of consolidated sales.
Greater China
Despite severe macroeconomic headwinds, including a real estate crisis and reduced government funding, the enterprise maintains robust direct operations and a newly opened technical center in Shanghai.
- $100,463,000 in revenue was realized in Greater China, comprising 8.24% of the global total.
- Low double-digit growth was recorded in this region during the final quarter of the fiscal year.
APAC, excluding Greater China
The broader Asia-Pacific region is serviced through a mix of direct sales offices and third-party distribution networks, capitalizing on emerging biopharmaceutical markets.
- $77,263,000 in revenue was generated, accounting for 6.33% of the total.
United Kingdom
The UK hosts significant operational capacity, specifically regarding the manufacturing operations of the Tocris brand.
- $54,827,000 in revenue was attributed to the UK, representing 4.50% of the total.
Rest of World
Global expansion continues through strategic partnerships, such as recent distribution agreements with Medsantek and Leader Life Sciences in Turkey and the Middle East.
- $37,547,000 in revenue was captured in these emerging markets, providing 3.08% of total sales.
Profit and Loss
The enterprise maintains a highly lucrative financial profile, characterized by strong gross margins and disciplined operational expense management .
| Consolidated Statements of Earnings (in thousands) | FY2025 | FY2024 | FY2023 |
| Net sales | $1,219,635 | $1,159,060 | $1,136,702 |
| Cost of sales | $429,363 | $389,335 | $366,887 |
| Gross margin | $790,272 | $769,725 | $769,815 |
| Selling, general and administrative | $588,521 | $466,375 | $378,378 |
| Research and development | $99,496 | $96,664 | $92,493 |
| Total operating expenses | $688,017 | $563,039 | $470,871 |
| Operating income | $102,255 | $206,686 | $298,944 |
| Interest expense | $(8,509) | $(15,736) | $(11,215) |
| Interest income | $3,886 | $3,323 | $3,410 |
| Other non-operating income (expense), net | $831 | $(8,584) | $47,520 |
| Earnings before income taxes | $98,463 | $185,689 | $338,659 |
| Income taxes | $25,063 | $17,584 | $53,217 |
| Net earnings | $73,400 | $168,105 | $285,442 |
- 64.8% GAAP gross margin was recorded for FY2025, impacted slightly by product mix and incentive accrual reinstatements.
- $122.1 million increase in SG&A expenses was driven by a non-recurring $37.2 million arbitration award and $80.5 million in asset impairment charges related to the held-for-sale Exosome business.
- 25.5% effective tax rate was realized in FY2025, a significant increase from the 9.5% rate in the prior year.
Balance Sheet
The balance sheet is heavily capitalized, featuring substantial liquidity to fund operations, debt service, and future acquisitions .
| Assets (in thousands) | June 30, 2025 | June 30, 2024 |
| Cash and cash equivalents | $162,186 | $151,791 |
| Short-term available-for-sale investments | $— | $1,072 |
| Accounts receivable, net | $206,876 | $241,394 |
| Inventories | $189,446 | $179,731 |
| Current assets held-for-sale | $12,332 | $9,773 |
| Other current assets | $37,460 | $33,658 |
| Total current assets | $608,300 | $617,419 |
| Property and equipment, net | $245,719 | $251,154 |
| Right-of-use assets | $73,399 | $91,285 |
| Goodwill | $980,935 | $972,663 |
| Intangible assets, net | $365,599 | $507,081 |
| Deferred tax asset | $10,307 | $— |
| Other assets | $273,609 | $264,265 |
| Total assets | $2,557,868 | $2,703,867 |
| Liabilities and Shareholders’ Equity (in thousands) | June 30, 2025 | June 30, 2024 |
| Trade accounts payable | $25,311 | $37,968 |
| Salaries, wages and related accruals | $65,791 | $49,818 |
| Accrued expenses | $25,663 | $24,886 |
| Contract liabilities | $32,571 | $27,930 |
| Income taxes payable | $10,770 | $3,706 |
| Operating lease liabilities – current | $14,098 | $12,920 |
| Other current liabilities | $1,645 | $2,151 |
| Total current liabilities | $175,849 | $159,379 |
| Deferred income taxes | $6,169 | $55,863 |
| Long-term debt obligations | $346,000 | $319,000 |
| Operating lease liabilities | $83,960 | $87,618 |
| Other long-term liabilities | $27,082 | $13,157 |
| Total liabilities | $639,060 | $635,017 |
| Common stock | $1,550 | $1,582 |
| Additional paid-in capital | $911,089 | $820,337 |
| Retained earnings | $1,066,049 | $1,325,247 |
| Accumulated other comprehensive loss | $(59,880) | $(78,316) |
| Total shareholders’ equity | $1,918,808 | $2,068,850 |
| Total liabilities and equity | $2,557,868 | $2,703,867 |
- $1.34 Billion in Goodwill and Intangibles represents over 52% of total assets, highlighting the historic reliance on M&A.
- $1 billion revolving credit facility is active, of which $346 million was drawn at year-end, providing massive unutilized liquidity.
Cash Flow
Bio-Techne operates a highly cash-generative model, converting robust operating margins into free cash flow to fund strategic investments and shareholder returns .
| Cash Flows (in thousands) | FY2025 | FY2024 | FY2023 |
| Net cash provided by operating activities | $287,556 | $298,981 | $254,393 |
| Additions to property and equipment | $(31,006) | $(62,877) | $(38,244) |
| Acquisitions, net of cash acquired | $— | $(169,707) | $(101,184) |
| Distributions from (Investments in) Wilson Wolf | $7,291 | $6,997 | $(232,000) |
| Investment in Spear Bio | $(15,000) | $— | $— |
| Proceeds from sale of assets held-for-sale | $2,447 | $— | $— |
| Other investing activities | $1,085 | $22,557 | $106,629 |
| Net cash used in investing activities | $(35,183) | $(203,030) | $(265,649) |
| Cash dividends | $(50,391) | $(50,419) | $(50,285) |
| Proceeds from stock option exercises | $51,739 | $60,935 | $29,813 |
| Re-purchases of common stock | $(275,731) | $(80,042) | $(19,562) |
| Borrowings under line-of-credit agreement | $104,000 | $225,000 | $619,661 |
| Repayments of long-term debt | $(77,000) | $(256,000) | $(525,661) |
| Taxes paid on RSUs and net share settlements | $(6,522) | $(21,872) | $(28,893) |
| Net cash provided by (used in) financing activities | $(253,905) | $(122,398) | $22,616 |
| Net change in cash and cash equivalents | $10,395 | $(28,780) | $8,004 |
- $275.7 million was deployed in massive open-market share repurchases, retiring 4,550,195 shares in FY2025 alone.
- $50.4 million in cash dividends were distributed, maintaining a strict $0.32 per share annual payout.
Board of Directors and Leadership Team
The executive leadership integrates deep scientific expertise with aggressive financial and corporate strategy acumen.
- Kim Kelderman (President, Chief Executive Officer and Director): Promoted to the top executive role in February 2024. Before joining Bio-Techne in 2018, Kelderman held executive positions at Thermo Fisher Scientific and Becton Dickinson.
- James Hippel (Executive Vice President and Chief Financial Officer): Appointed in 2014, Hippel previously served as CFO for Mirion Technologies and VP of Finance at Thermo Fisher Scientific.
- William Geist (President, Protein Sciences): Joined in 2022 from Quanterix, where he was COO.
- Matthew McManus (President, Diagnostics and Spatial Biology): Joined in 2024. He previously served as CEO of Asuragen before its acquisition.
- Shane Bohnen (Senior Vice President, General Counsel & Corp. Secretary): Promoted in 2023, bringing 10 years of private practice experience as a life sciences litigator.
- Martin Wirtz (Senior Vice President, Strategy and Corporate Development): Joined from Danaher, where he oversaw strategy for the diagnostics division.
- Cheryl Bethune (Senior Vice President and Chief Human Resources Officer): Recruited after a 20-year tenure steering HR strategies at General Mills.
Board of Directors: The Board relies on diverse academic and corporate backgrounds to guide governance .
- Robert V. Baumgartner (Chairman)
- Julie Bushman
- Dr. Rupert Vessey
- Dr. Joseph Keegan
- John L. Higgins
- Dr. Roeland Nusse
- Dr. Alpna Seth
- Dr. Judith Klimovsky
- Dr. Amy E. Herr: Chancellor’s Professor of Bioengineering at UC Berkeley; provides deep biological engineering insight.
- Kim Kelderman
Subsidiaries, Associates, Joint Ventures
Bio-Techne predominantly operates through wholly-owned subsidiaries acquired over decades of M&A activity. The enterprise does, however, maintain highly strategic collaborative structures.
- ScaleReady LLC: A collaborative marketing venture operated in partnership with Wilson Wolf and an unnamed third party. This venture is designed to provide integrated, scalable solutions specifically for the explosive cell and gene therapy market.
Other Investments
Management executes targeted minority investments to secure access to disruptive technologies before attempting full consolidation.
Wilson Wolf Corporation
- Ownership Percentage: 19.9%
- Nature of Investment: Equity Method Investment
- Carrying Value: $235,983,000 (as of June 30, 2025)
- Business Activity: Innovator behind the G-Rex bioreactor, an essential device for scaling cell therapy manufacturing.
- Strategic Profile: Bio-Techne paid $232 million for its stake in March 2023. A forward contract obligates Bio-Techne to purchase the remaining 80.1% by December 31, 2027, based on a ~4.4x revenue multiple, with the total payout estimated around $1 billion. The asset achieved over 20% growth and 70% EBITDA margins in FY2025.
Spear Bio
- Ownership Percentage: Minority (Undisclosed exact %)
- Nature of Investment: Strategic
- Investment Value: $15,000,000
- Business Activity: Developer of ultra-sensitive assays targeting Alzheimer’s disease research.
- Strategic Profile: The investment was executed at the beginning of fiscal 2025 to secure a distribution agreement for state-of-the-art neurodegenerative diagnostics.
Physical Properties
The enterprise manages a complex web of highly regulated manufacturing facilities and administrative hubs globally .
Owned Properties:
- Minneapolis, Minnesota: The 800,000 square foot global headquarters. 710,000 square feet are utilized by both segments for R&D, manufacturing, and administration .
- Saint Paul, Minnesota: A 61,000 square foot manufacturing facility.
- Wallingford, Connecticut: A 53,000 square foot Protein Sciences plant.
- Abingdon, United Kingdom: A 16,000 square foot European operational hub.
- Toronto, Canada: A 9,000 square foot Protein Sciences facility.
- Flowery Branch, Georgia: A 34,000 square foot manufacturing plant, currently held for sale.
Leased Properties:
- San Jose, California: 98,000 square foot ProteinSimple manufacturing and office site.
- Centennial, Colorado: 74,000 square foot Novus Biologicals warehouse and office.
- Devens, Massachusetts: 70,000 square foot Bionostics plant.
- San Marcos, California: 63,000 square foot Cliniqa facility.
- Shanghai, China: 59,000 square foot PrimeGene manufacturing lab.
- Newark, California: 56,000 square foot Advanced Cell Diagnostics plant.
- Austin, Texas: 47,000 square foot Asuragen facility.
- Bristol, United Kingdom: 41,000 square foot Tocris laboratory and manufacturing plant.
- Waltham, Massachusetts: 38,000 square foot Exosome Diagnostics lab.
- Shanghai and Beijing, China: 34,000 square foot regional offices.
- Tolochenaz, Switzerland: 26,000 square foot Lunaphore facility.
- Dublin, Ireland: 25,000 square foot warehouse.
- Ottawa, Canada: 11,000 square foot ProteinSimple plant.
- Rennes, France: 11,000 square foot regional office.
Founders
The enterprise traces its genesis to 1976, officially launching under the moniker Research and Diagnostic Systems, Inc. Following nearly a decade of private growth, the entity executed a merger with Techne Corporation in 1985 to facilitate its transition to the public markets, later rebranding to Bio-Techne Corporation.
Parent
Bio-Techne Corporation stands as the ultimate parent entity. It operates independently as a publicly traded company on the NASDAQ exchange and is not a subsidiary of any overarching conglomerate.
Investments and Capital Expenditure Plans
To sustain its technological moat, management commits massive capital to internal expansion and innovation.
- $31,006,000 in Capital Expenditures was deployed in fiscal 2025, heavily targeted toward establishing new building infrastructure, scaling machinery, and upgrading IT equipment.
- $42 million in planned Capex is earmarked for fiscal 2026, which will be financed entirely through operating cash flows and existing liquidity.
- $99,496,000 in R&D Spending was executed in FY2025 to develop advanced generative AI models for designer proteins and next-generation spatial biology assays.
Shareholding Pattern
Bio-Techne is widely held by a diverse base of institutional and retail investors. As of August 18, 2025, there were exactly 155,549,587 shares of Common Stock outstanding.
- Over 170,000 beneficial shareholders and more than 110 record holders maintain equity in the enterprise.
- $11.4 Billion represented the aggregate market value of the Common Stock held exclusively by non-affiliates as of December 31, 2024, calculated at a $72.03 per share closing price.
Future Strategy
Executive leadership has meticulously outlined a multi-vectored strategy to capture emerging biotechnological markets.
- Grow & Leverage the Core: Utilizing vast key opinion leader networks to ensure high-margin legacy reagents maintain market dominance.
- Capitalize on High Potential Markets: Redirecting massive investments into the rapidly scaling cell and gene therapy manufacturing sectors, specifically via the impending $1 billion buyout of Wilson Wolf.
- Market Expansion Through Acquisition: Actively scanning the M&A landscape to acquire highly differentiated technologies that fill pipeline gaps, as evidenced by the Lunaphore integration.
- Best-in-Class Experience: Expanding digital and physical distribution networks globally, highlighted by the planned 2026 launch of the Düsseldorf Customer Service Center.
Key Strengths
- Unmatched Sector Profitability: A 42.6% adjusted operating margin in the Protein Sciences segment provides the enterprise with a massive cash buffer to withstand macroeconomic volatility.
- Entrenched Scientific Moat: The company’s products are deeply embedded in academic and commercial research, evidenced by over 32,000 peer-reviewed citations in calendar 2024 alone.
- Proprietary Generative AI: The enterprise is actively leveraging five decades of proprietary biological data to train AI models capable of engineering novel, patentable “designer proteins” with hyperactive properties.
Key Challenges and Risks
- Macroeconomic Biotech Funding: The life sciences tools industry is highly sensitive to venture capital and IPO funding levels. High interest rates severely depressed funding for early-stage biopharma clients in the latter half of the fiscal year.
- Geopolitical and Tariff Vulnerabilities: Operations rely heavily on global supply chains. Ongoing trade tensions and retaliatory tariffs between the U.S. and China threaten to increase input costs and disrupt distribution in a critical growth market.
- Academic Funding Cuts: A heavy reliance on university researchers exposes the company to legislative risks, such as proposed 40% cuts to the NIH budget and 15% caps on indirect funds.
- Regulatory Compliance Burdens: The transition to the new In Vitro Diagnostic Regulation (IVDR) in Europe requires material modifications to quality systems and clinical data requirements, risking massive compliance costs and product delays.
Conclusion and Strategic Outlook
Bio-Techne Corporation operates as an indispensable, highly lucrative fulcrum within the global life sciences sector. By seamlessly integrating high-margin, consumable biological reagents with sophisticated analytical capital equipment, the enterprise captures economic value across the entire lifecycle of drug discovery and clinical diagnostics. While the company faces distinct headwinds—ranging from constrained venture capital funding in the biotech sector to escalating geopolitical trade tensions—its flawless execution of organic expansion and targeted acquisitions provides a robust shield. The impending full consolidation of Wilson Wolf’s cell therapy manufacturing capabilities, combined with the explosive growth of the Lunaphore spatial biology platform, positions Bio-Techne to dominate the next decade of advanced therapeutics and precision medicine.
FAQ Section
What is Bio-Techne Corporation’s primary business model?
Bio-Techne develops, manufactures, and globally distributes high-quality life science reagents, analytical instruments, and precision diagnostics used to investigate biological processes and manufacture advanced therapeutics.
How much revenue did Bio-Techne generate in its latest fiscal year?
In fiscal year 2025, the company generated $1.219 billion in consolidated net sales, representing a 5% organic growth rate.
What are Bio-Techne’s main reporting segments?
The enterprise operates through two primary segments: Protein Sciences (accounting for over 70% of revenue) and Diagnostics and Spatial Biology.
What is the “Leo” instrument platform?
Leo is Bio-Techne’s latest high-throughput Simple Western instrument, designed to provide researchers with enhanced efficiency, flexibility, and automated quantitative protein analysis.
Who is the Chief Executive Officer of Bio-Techne?
Kim Kelderman serves as the President and Chief Executive Officer, having assumed the position in February 2024.
Does Bio-Techne pay a dividend to its shareholders?
Yes, the company distributed over $50.3 million in cash dividends during fiscal year 2025.
Where are Bio-Techne’s global headquarters located?
The company operates out of a massive 800,000-square-foot owned complex in Minneapolis, Minnesota.
Official Site: https://www.bio-techne.com
Source: Content on FirmsWorld.com is based on publicly available corporate filings, regulatory disclosures, annual reports, SEC 10-K filings, investor relations materials, and, where applicable, direct communications with the company.
